NORADRENALINE AGUETTANT 1MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION [SIN15593P]
Active ingredients: NORADRENALINE AGUETTANT 1MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION
Last updated 24 April 2026
Product Info
NORADRENALINE AGUETTANT 1MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION
[SIN15593P]
Product information
Active Ingredient and Strength | NORADRENALINE TARTRATE 2 MG/ML EQUIV. NORADRENALINE - 1 MG/ML |
Dosage Form | INFUSION, SOLUTION CONCENTRATE |
Manufacturer and Country | LABORATOIRE AGUETTANT - FRANCE |
Registration Number | SIN15593P |
Licence Holder | INTEGA PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | C01CA03 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
1 INDICATIONS AND USAGE
NORADRENALINE AGUETTANT is indicated to raise blood pressure in adult patients with severe, acute hypotension.
Dosing
2 DOSAGE AND ADMINISTRATION
2.1 Important Dosage and Administration Instructions
Correct Hypovolemia
Address hypovolemia before initiation of NORADRENALINE AGUETTANT therapy. If the patient does not respond to therapy, suspect occult hypovolemia [see Warnings and Precautions (5.1) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].
Administration
Dilute NORADRENALINE AGUETTANT prior to use [see Dosage and Administration (2.3)].
Infuse NORADRENALINE AGUETTANT into a large vein. Avoid infusions into the veins of the leg in the elderly or in patients with occlusive vascular disease of the legs [see Warnings and Precautions (5.1) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information]. Avoid using a catheter-tie-in technique.
Discontinuation
When discontinuing the infusion, reduce the flow rate gradually. Avoid abrupt withdrawal.
2.2 Dosage
After an initial dosage of 8 to 12 mcg per minute via intravenous infusion, assess patient response and adjust dosage to maintain desired hemodynamic effect. Monitor blood pressure every two minutes until the desired hemodynamic effect is achieved, and then monitor blood pressure every five minutes for the duration of the infusion.
Typical maintenance intravenous dosage is 2 to 4 mcg per minute.
2.3 Preparation of Diluted Solution
Visually inspect NORADRENALINE AGUETTANT for particulate matter and discoloration prior to administration (the solution is colorless to slightly yellow). Do not use the solution if its color is pinkish or darker than slightly yellow or if it contains a precipitate.
Add the content of one NORADRENALINE AGUETTANT ampule (4 mg in 4 mL) to 1,000 mL of 5% Dextrose, 0.9% sodium chloride or isotonic dextrose saline to produce a 4 mcg per mL dilution. Dextrose reduces loss of potency due to oxidation.
Use higher concentration solutions in patients requiring fluid restriction.
2.4 Drug Incompatibilities
Avoid contact with iron salts, alkalis, or oxidizing agents.
Whole blood or plasma, if indicated to increase blood volume, should be administered separately.
Contraindications
4 CONTRAINDICATIONS
None.